Rhein alleviates advanced glycation end products (AGEs)-induced inflammatory injury of diabetic cardiomyopathy in vitro and in vivo models

• Published in: Journal of natural medicines 2023-09, Vol.77 (4), p.898-915
• Main Authors: Zhao, Shao-Yang, Zhao, Huan-Huan, Wang, Bao-Hua, Shao, Cui, Pan, Wen-Jun, Li, Sai-Mei
• Format: Article
• Language: English
• Subjects: Advanced glycosylation end products; Animals; Anthraquinone; Anthraquinones - pharmacology; Anthraquinones - therapeutic use; Anti-inflammatory agents; Biomedical and Life Sciences; Biomedicine; Cardiomyopathy; Complementary & Alternative Medicine; Diabetes; Diabetes Mellitus; Diabetic Cardiomyopathies - drug therapy; Drug development; Glycation End Products, Advanced; Glycosylation; I-kappa B Kinase; Inflammation; Macrophages; MAP kinase; Medicinal Chemistry; NF-kappa B; NF-κB protein; Nitric-oxide synthase; Original Paper; Pharmacology/Toxicology; Pharmacy; Phosphorylation; Plant Sciences; Prostaglandin E2; Protein Serine-Threonine Kinases; Rats; TNF Receptor-Associated Factor 6; TRAF6 protein; Tumor necrosis factor-α
• ISSN: 1340-3443; 1861-0293
• DOI: 10.1007/s11418-023-01741-7

In diabetic patients, diabetic cardiomyopathy (DCM) is one of the most common causes of death. The inflammatory response is essential in the pathogenesis of DCM. Rhein, an anthraquinone compound, is extracted from the herb rhubarb, demonstrating various biological activities. However, it is unclear whether rhein has an anti-inflammatory effect in treating DCM. In our research, we investigated the anti-inflammatory properties as well as its possible mechanism. According to the findings in vitro, rhein could to exert an anti-inflammatory effect by reducing the production of NO, TNF-α, PGE 2 , iNOS, and COX-2 in RAW264.7 cells that had been stimulated with advanced glycosylation end products (AGEs). In addition, rhein alleviated H9C2 cells inflammation injury stimulated by AGEs/macrophage conditioned medium (CM). In vivo have depicted that continuous gavage of rhein could improve cardiac function and pathological changes. Moreover, it could inhibit the accumulation of AGEs and infiltration of inflammatory factors inside the heart of rats having DCM. Mechanism study showed rhein could suppress IKKβ and IκB phosphorylation via down-regulating TRAF6 expression to inhibit NF-κB pathway in AGEs/CM-induced H9C2 cells. Moreover, the anti-inflammation effect of rhein was realized through down-regulation phosphorylation of JNK MAPK. Furthermore, we found JNK MAPK could crosstalk with NF-κB pathway by regulating IκB phosphorylation without affecting IKKβ activity. And hence, the protective mechanism of rhein may involve the inhibiting of the TRAF6-NF/κB pathway, the JNK MAPK pathway, and the crosstalk between the two pathways. These results suggested that rhein may be a promising drug candidate in anti-inflammation and inflammation-related DCM therapy. Graphical abstract